- Home
- CELC vs FRSH Comparison
CELC vs FRSH Comparison
Compare CELC & FRSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- FRSH
- Stock Information
- Founded
- CELC 2011
- FRSH 2010
- Country
- CELC United States
- FRSH United States
- Employees
- CELC N/A
- FRSH N/A
- Industry
- CELC Medical Specialities
- FRSH EDP Services
- Sector
- CELC Health Care
- FRSH Technology
- Exchange
- CELC Nasdaq
- FRSH Nasdaq
- Market Cap
- CELC 3.1B
- FRSH 3.7B
- IPO Year
- CELC 2017
- FRSH 2021
- Fundamental
- Price
- CELC $74.11
- FRSH $10.88
- Analyst Decision
- CELC Strong Buy
- FRSH Buy
- Analyst Count
- CELC 5
- FRSH 16
- Target Price
- CELC $69.40
- FRSH $19.44
- AVG Volume (30 Days)
- CELC 1.4M
- FRSH 3.5M
- Earning Date
- CELC 11-12-2025
- FRSH 11-05-2025
- Dividend Yield
- CELC N/A
- FRSH N/A
- EPS Growth
- CELC N/A
- FRSH N/A
- EPS
- CELC N/A
- FRSH N/A
- Revenue
- CELC N/A
- FRSH $810,640,000.00
- Revenue This Year
- CELC N/A
- FRSH $17.01
- Revenue Next Year
- CELC N/A
- FRSH $13.02
- P/E Ratio
- CELC N/A
- FRSH N/A
- Revenue Growth
- CELC N/A
- FRSH 18.18
- 52 Week Low
- CELC $7.58
- FRSH $10.51
- 52 Week High
- CELC $83.00
- FRSH $19.77
- Technical
- Relative Strength Index (RSI)
- CELC 64.02
- FRSH 37.37
- Support Level
- CELC $71.06
- FRSH $10.79
- Resistance Level
- CELC $79.97
- FRSH $11.32
- Average True Range (ATR)
- CELC 5.13
- FRSH 0.33
- MACD
- CELC 0.11
- FRSH 0.03
- Stochastic Oscillator
- CELC 53.43
- FRSH 31.58
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About FRSH Freshworks Inc.
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CS and ITSM categories and has also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and serve their customers and employees. The group derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and Other regions.